Daten zu BAY 59-7939 auf dem XXth Kongress der International Society on Thrombosis & Haemostasis (ISTH)

6. - 12. August 2005 in Sydney, Australien


8. August 2005 ab 14:00 Uhr MESZ (12:00 Uhr GMT):
IR Telefonkonferenz - ISTH Review 2005

Die Audio-Aufzeichnung dieser Veranstaltung ist nicht mehr verfügbar.

Hintergrundinformationen (nur in Englisch verfügbar)
Thromboembolic disorders: A major cause of morbidity and mortalityDownload ( PDF, 248 KB ) sammeln
Current anticoagulant therapiesDownload ( PDF, 241 KB ) sammeln
Coagulation PathwayDownload ( PDF, 81 KB ) sammeln
GlossarDownload ( PDF, 103 KB ) sammeln

ISTH 2005 Abstracts zu BAY 59-7939

An Oral, Direct Factor Xa Inhibitor – BAY 59-7939 – For Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: A Dose-ranging Study

Prevention Of Venous Thromboembolism With An Oral, Direct Factor Xa Inhibitor – BAY 59-7939 – In Elective Hip Replacement: A Dose-Ranging Study

Aspirin Has No Effect on the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY 59-7939 – an Oral, Direct Factor Xa Inhibitor

Interaction Of BAY 59-7939 – A Novel, Oral, Direct Factor Xa Inhibitor – With Antiplatelet Agents: Monitoring And Therapeutic Applications

Effect Of BAY 59-7939 – A Novel, Oral, Direct Factor Xa Inhibitor – on Clot-Bound Factor Xa Activity In Vitro

Effect of Enoxaparin on the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY 59-7939 – an Oral, Direct, Factor Xa Inhibitor

The Oral, Direct Factor Xa Inhibitor – BAY 59-7939 – Inhibits Thrombin Generation In Vitro After Tissue Factor Pathway Activation

Antithrombotic Mechanism of Action of BAY 59-7939 – a Novel, Oral, Direct Factor Xa Inhibitor

Comparison of the Anticoagulant Properties of BAY 59-7939 – an Oral, Direct Factor Xa Inhibitor – with Fondaparinux and Enoxaparin

Letzte Änderung: 13. Januar 2014 Copyright © Bayer AG